The American Academy of Allergy, Asthma & Immunology (AAAAI) and the World Allergy Organization (WAO) recently convened for their Joint Congress in San Diego, California from February 28 to March 3. This esteemed event brought together experts to explore the vital connection between climate change and allergic diseases, shedding light on their profound impact on global health.
Highlighted below are concise overviews of research studies showcased at the 2025 AAAAI/WAO Joint Congress that center on chronic rhinosinusitis.
Results Of An International Survey In Adults With CRSwNP: Surgery Or Biologics?
- Numerous biologics have received approval for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The objective of our international survey was to gain insight into patients' perspectives on the current treatment options available.
- It appears that the majority of individuals with CRSwNP are being managed with intranasal medications or surgical intervention, despite the existence of biologic therapies. Surprisingly, half of those who underwent surgery did not report being presented with the opportunity to explore biologics as an alternative treatment. This highlights the potential benefits of enhancing shared decision-making processes to ensure that patients are fully informed about all available options for managing their nasal polyps.
A Study of Dupilumab in Adults with CRSsNP: Results from the Liberty ORION study
- Chronic rhinosinusitis without nasal polyps (CRSsNP) is a chronic inflammatory condition affecting the nasal cavities and sinuses. It is characterized by symptoms such as nasal obstruction, discharge, facial pain, pressure, and reduced sense of smell lasting for at least 12 weeks. The Liberty ORION study aimed to investigate the effectiveness of dupilumab in improving signs and symptoms of CRSsNP in patients with evidence of type 2 inflammation.
- The study found that patients with CRSsNP and screening eosinophils levels of 300 cells/mm3 or higher who were treated with dupilumab experienced significant improvement in their symptoms. Specifically, at Week 24, these patients showed clinically meaningful enhancements in LMK-CT scores compared to those who received a placebo. Additionally, improvements were observed in SNOT-22, sTSS, and UPSIT scores in the dupilumab group.
- Overall, the findings suggest that dupilumab treatment may be beneficial in managing CRSsNP in patients with evidence of type 2 inflammation. Further research is needed to fully understand the potential of dupilumab in treating this condition.
- Depemokimab represents a groundbreaking advancement in biologic therapy, being the first ultra-long-acting medication engineered with enhanced interleukin-5 binding affinity, high potency, and an extended half-life. This innovative formulation allows for twice-yearly dosing, providing patients with a convenient and effective treatment option.
- The efficacy and safety of depemokimab were rigorously evaluated in the replicate ANCHOR-1/2 studies. These studies demonstrated that twice-yearly depemokimab significantly improved clinically relevant coprimary endpoints. Furthermore, the medication exhibited a well-tolerated safety profile, reassuring both patients and healthcare providers of its reliability and effectiveness. In conclusion, the findings from the ANCHOR-1/2 studies support the use of depemokimab as a promising treatment option for individuals with certain medical conditions
- Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) have been shown to have a negative impact on the activity levels of patients. In a post hoc analysis conducted, the effect of tezepelumab on activity-related items in the Asthma Quality of Life Questionnaire (standardized) for patients aged 12 and above (AQLQ[S]+12) was evaluated in patients with a history of CRSwNP from the NAVIGATOR study (NCT03347279).
- The findings of the study revealed that patients with severe, uncontrolled asthma and a history of CRSwNP who were treated with tezepelumab experienced significant improvements in their activity levels compared to those who received a placebo. This suggests that tezepelumab may be an effective treatment option for patients with severe asthma and CRSwNP.
Chronic Rhinosinusitis with or without Nasal Polyps in Patients with Primary Antibody Deficiencies
- The prevalence of chronic rhinosinusitis (CRS) in the general population ranges from 5-12%. Approximately 25-30% of individuals with CRS also have nasal polyps, known as CRS with nasal polyps (CRSwNP). This study seeks to explore the prevalence and characteristics of CRSwNP in patients with primary antibody deficiencies (PADs).
- Preliminary findings suggest a higher prevalence of CRS in individuals with PADs, while the proportion of CRSwNP among patients with CRS remains consistent with that of the general population. Research endeavors such as this one have the potential to enhance our understanding of the underlying mechanisms of CRS, both with and without nasal polyps.
Assessing the Effect of BMI Status on Chronic Rhinosinusitis Immunopathology
- Previous research has shown a correlation between obesity and a higher incidence of chronic rhinosinusitis (CRS). Obesity is often linked to inflammation, which may play a role in the development of CRS. The aim of the current study was to examine how different levels of obesity could impact the pathogenic characteristics of CRS. The dataset is the most extensive analysis of CRS severity among various body mass index (BMI) categories to date.
- Although previous studies have indicated a higher prevalence of CRS in obese individuals, these findings suggest that obesity does not necessarily indicate a more severe clinical presentation of sinus inflammation in cases of CRS.
- Tezepelumab, a human monoclonal antibody, effectively inhibits the activity of thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine that plays a crucial role in the development of chronic rhinosinusitis with nasal polyps (CRSwNP). The WAYPOINT study (NCT04851964) was conducted to assess the efficacy and safety of tezepelumab in adults suffering from severe CRSwNP.
- The findings of the study revealed that tezepelumab significantly reduced the severity of nasal polyps and decreased the necessity for nasal polyp surgery or systemic corticosteroid treatment. Additionally, patients reported an improvement in sino-nasal symptoms when compared to those who received a placebo. These results highlight the potential of tezepelumab as a promising treatment option for adults with severe CRSwNP.
Assessment of patient satisfaction with dupilumab for chronic rhinosinusitis with nasal polyps
- The monoclonal antibody Dupilumab, which targets the IL-4/IL-13 receptor, has been approved for the treatment of severe and recurrent chronic rhinosinusitis with nasal polyps (CRSwNP). Studies have shown that Dupilumab is effective in reducing nasal polyps and improving olfaction. However, there is a lack of sufficient research on patient satisfaction with Dupilumab.
- In a recent study, researchers concluded that treatment with Dupilumab for CRSwNP may lead to increased patient satisfaction, particularly in those with comorbid asthma. It was also noted that the interval of injection may impact the effectiveness of Dupilumab treatment.
- Overall, Dupilumab shows promise in the treatment of CRSwNP, with potential benefits for patient satisfaction, especially in those with additional health conditions such as asthma. Further research is needed to fully understand the impact of Dupilumab on patient outcomes.
The #AAAAI25 is set to be an enriching and informative event. We recommend clicking here to explore the comprehensive list of topics and sessions that will be covered at this significant event. Don’t miss the opportunity to expand your expertise.
Sign up for alerts and stay informed on the latest published guidelines and stay tuned for our recap post the conference.
Copyright © 2025 Guideline Central, All Rights Reserved.